Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...

Kennedy Jr.'s secretary of the Department of Health and Human Services (HHS) confirmation hearing and how pharma stocks like Pfizer (PFE) and Merck (MRK) may be impacted: "There's been a lot of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is based on objective response rate and ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go before the patents protecting the original version expire. Keytruda ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...